A comprehensive portal site for Medical Innovation Support Office (MEDISO).Medical Innovation Support Office

Hitoshi Takuma

Akihiko Okuno

SK Intellectual Property Law Firm (SKIP) Managing Partner
SCM BioMedica Co., Ltd. Co-Founder

Master's degree in Cell Structure Research, Department of Applied Bioengineering, Graduate School of Agriculture and Life Sciences, University of Tokyo, Japanese Patent Attorney, Information Security Administrator, and JPAA Intellectual Property Management Consultant certification. As a FoundX supporter of the University of Tokyo,　He supports the intellectual property strategies of many IT and bio-related startups. He specializes in supporting the planning of intellectual property strategies in a variety of fields including biotechnology, pharmaceuticals, and medical devices. In addition, together with Dr. Yoshimasa Tanaka of Nagasaki University (a genius researcher who developed Opdivo with annual sales of over 1 trillion yen together with Dr. Tasuku Honjo, winner of the Nobel Prize in Medicine and Physiology), he established SCM Biomedica Co., Ltd. He co-founded the company and is currently trying to manage his own drug discovery startup.

Takahiro Mizumoto

Ant innovations Co., Ltd

Kyoto University Graduate School of Medicine, Master’s Program in Intellectual Property Management.
After passing the Japanese Patent Attorney Examination, gained venture investment experience in high-tech sectors including IT and healthcare at NIFS SMBC Capital (later split into Daiwa Corporate Investment and SMBC Venture Capital).
Subsequently joined Showa Shell Sekiyu, where he led the planning and development of multiple new services spanning payment solutions, retail electricity, and mobile app businesses. With the launch of the University of Tokyo Innovation Platform (UTokyo IPC), he joined the firm and founded 1stRound, a cross-university incubation program. He later spearheaded the establishment of an approximately JPY 25 billion open-innovation promotion fund and served as its Chief Investment Officer.
In November 2025, he founded Ant Innovations, a newly established venture capital firm and subsidiary of the private equity firm Ant Capital Partners, and assumed the role of Representative Director and Partner.

Tomoyo Mori

Fast Track Initiative, Inc.　Capitalist

Tomoyo obtained her medical license and began her career by engaging in training and clinical practice in medically underserved areas. She then joined the Department of Cardiovascular Medicine at Tokyo Women's Medical University Hospital, where she treated patients with heart failure, heart transplants, and myocardial infarctions. At the university hospital, she also participated in clinical trials for medical device startups. In parallel with her clinical work, she was involved in domestic and international business development for medical device startups and led a team while participating in U.S.-based MedTech accelerators (MedTech Innovator, Fogarty Innovation). She holds an MBA from the University of Michigan's Ross School of Business and is a board-certified internist by the Japanese Medical Specialty Board as well as a certified occupational physician by the Japan Medical Association. Currently, she is part of Fast Track Initiative, where she focuses on investment, company creation, and business development for medical device startups.

Yoshimi Naruo

Orizuru Therapeuics, Inc. Associate Director, IP&Legal Ph.D., Patent attorney

Education: Ph.D. in Bioinformatics/Systems Biology, Tokyo Medical and Dental University. Conducted research in systems biology at RIKEN for 3 years (student internship). Experience: 5 years of experience in drug regulatory affairs at an originator pharmaceutical company, followed by 2 years as an in-house IP specialist handling invalidation and infringement matters at a generic pharmaceutical company. Patent prosecution primarily in the fields of pharmaceuticals, biotechnology, and food at an IP law firm. Fulfilling a long-held aspiration to join a startup, she took on the role of Vice President of Legal IP & Strategy at Splink, Inc., where she contributed to winning the Grand Prix at the 3rd IP BASE AWARD hosted by the Japan Patent Office and the 2022 WIPO Global Awards hosted by the World Intellectual Property Organization (WIPO). Currently, she is responsible for intellectual property and legal affairs at Orizuru Therapeutics, Inc., a company aiming to commercialize regenerative medicine derived from iPS cells. She leads the formulation of IP strategies and the development of an IP portfolio. Her strength lies in creating IP strategies with a focus on pharmaceutical regulatory affairs, and she strives to provide practical advice in the face of limited resources and uncertainties surrounding technology and commercialization.